8-K: Denali Therapeutics Announces 2025 Milestones, Prioritizes Neurodegeneration and Lysosomal Storage Disease Portfolio

Denali Therapeutics outlines key milestones for 2025, including a BLA submission for tividenofusp alfa and advancing its TransportVehicleTM (TV) enabled programs.

Summary

• Denali Therapeutics announced its anticipated milestones for 2025, focusing on advancing its therapeutics portfolio for neurodegenerative and lysosomal storage diseases.
• A key highlight is the planned submission of a Biologics License Application (BLA) for tividenofusp alfa for Hunter syndrome in early 2025, with preparations underway for a commercial launch in late 2025 or early 2026.
• Denali will seek FDA alignment on an accelerated approval pathway for DNL126 for Sanfilippo syndrome Type A.
• The company plans to expand its TransportVehicleTM (TV) enabled programs, aiming to advance one to two additional TV programs into the clinic each year for the next three years.
• Denali's cash, cash equivalents, and marketable securities were approximately $1.28 billion as of September 30, 2024, which is expected to fund operations into 2028.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the Breakthrough Therapy Designation, planned BLA submission, and expansion of the TV-enabled portfolio. However, the failed primary endpoint in the DNL343 trial tempers the overall outlook.

Positives

• Tividenofusp alfa received Breakthrough Therapy Designation from the FDA, potentially accelerating its approval for Hunter syndrome.
• Preliminary data for DNL126 showed promising results in reducing CSF HS levels, supporting a potential accelerated approval pathway.
• DNL126 has Orphan Disease designation, Fast Track status, and has been selected for the FDA Support for clinical Trials Advancing Rare disease Therapeutics (START) program.
• DNL593 demonstrated robust brain delivery in healthy volunteers, indicating potential for treating FTD-GRN.
• Denali's strong cash position provides a runway into 2028, allowing for continued investment in its pipeline.

Negatives

• The Phase 2/3 HEALEY ALS platform trial for DNL343 did not meet the primary endpoint, although further analyses are anticipated.
• The company is dependent on successful development of its BBB platform technology and TV-enabled product candidates.

Risks

• Clinical trial results may differ from preclinical, early clinical, preliminary, or expected results.
• There is a risk of significant adverse events, toxicities, or other undesirable side effects.
• Product candidates may not receive regulatory approval necessary to be commercialized.
• Developments relating to Denali's competitors and its industry, including competing product candidates and therapies, could impact Denali's success.
• Denali's ability to obtain, maintain, or protect intellectual property rights is crucial for its long-term viability.

Future Outlook

Denali anticipates submitting a BLA for tividenofusp alfa in early 2025 and preparing for its commercial launch. The company also plans to seek FDA alignment on an accelerated approval path for DNL126 and advance one to two additional TV programs into the clinic each year for the next three years.

Management Comments

• 'In 2025, we are on track to submit our first BLA for tividenofusp alfa for Hunter syndrome and prepare for commercial launch,' said Ryan Watts, Ph.D., Chief Executive Officer of Denali.
• Ryan Watts also stated that they will seek alignment with the FDA on an accelerated approval path for DNL126 for Sanfilippo syndrome.
• Watts added that they expect these two programs to be the foundation of a broad franchise of TransportVehicleTM (TV) enabled enzyme replacement therapies.
• Watts mentioned that they are expanding their TV-enabled portfolio and plan to advance one to two additional TV programs into the clinic each year for the next three years.

Industry Context

Denali's focus on neurodegenerative and lysosomal storage diseases aligns with the growing need for innovative therapies in these areas. The TransportVehicleTM (TV) platform represents a novel approach to drug delivery across the blood-brain barrier, a significant challenge in treating brain disorders. The collaborations with Biogen and Takeda highlight the industry's interest in Denali's technology and pipeline.

Comparison to Industry Standards

• Denali's TransportVehicleTM (TV) platform aims to improve drug delivery across the blood-brain barrier, a challenge also addressed by companies like Bioasis Technologies and Neurimmune.
• The development of enzyme replacement therapies for lysosomal storage disorders is a competitive field, with companies like Sanofi Genzyme (Aldurazyme for MPS I) and BioMarin Pharmaceutical (Vimizim for MPS IVA) already having approved products.
• Denali's collaboration with Biogen on LRRK2 inhibitors for Parkinson's disease puts them in competition with other companies developing similar therapies, such as Genentech (Roche) and UCB.
• The focus on accelerated approval pathways for rare diseases is a common strategy in the biopharmaceutical industry, as seen with Sarepta Therapeutics' Exondys 51 for Duchenne muscular dystrophy.

Stakeholder Impact

• Shareholders: Potential for increased value through pipeline advancement and commercialization.
• Patients: Access to new therapies for neurodegenerative and lysosomal storage diseases.
• Employees: Continued employment and growth opportunities within the company.
• Partners: Collaboration opportunities with Biogen, Takeda, and Sanofi.

Next Steps

• Submit a biologics license agreement (BLA) for tividenofusp alfa in early 2025.
• Prepare for the U.S. launch of tividenofusp alfa in late 2025 or early 2026.
• Seek alignment with the FDA on a path for accelerated approval for DNL126.
• Advance one to two additional TV programs into the clinic per year over the next three years.
• Further analyses of DNL343 data, including neurofilament light (NfL) and other fluid biomarkers.

Key Dates